OBJECTIVES: The aims of the detection of hypermethylated RASSF1A gene in maternal plasma from all three trimesters of pregnancy were to show its feature of cell-free fetal DNA and to make up deficients of genetic markers. This study also aimed at investigating of its application value in pre-eclampsia compared with third trimester. METHODS: Eighty pregnant women (7-41 gestational weeks) including normal pregnant women (60 cases) and pre-eclamptic pregnant women (20 cases) were selected as study groups and 20 normal non-pregnant women were selected as control group. Free DNA of plasma samples was extracted, and RASSF1A levels before and after double-methylation-sensitive restriction enzyme digestion of HinP1I and HhaI were determined to measure total and fetal cell-free DNA, respectively. beta-Actin gene was detected as a control to confirm complete enzyme digestion. RESULTS: The median concentrations of hypermethylated RASSF1A gene were 46 copies/mL in first trimester, 96 copies/mL in second trimester, 527 copies/mL in third trimester and 1947 copies/mL in pre-eclampsia. There was positive correlation between fetal-derived hypermethylated RASSF1A levels and the severity of pre-eclampsia. CONCLUSION: Hypermethylated RASSF1A gene may be considered as an epigenetic marker to detect the fetal DNA in maternal plasma and expands the clinical application of non-invasive prenatal diagnosis. (c) 2010 John Wiley & Sons, Ltd.
OBJECTIVES: The aims of the detection of hypermethylated RASSF1A gene in maternal plasma from all three trimesters of pregnancy were to show its feature of cell-free fetal DNA and to make up deficients of genetic markers. This study also aimed at investigating of its application value in pre-eclampsia compared with third trimester. METHODS: Eighty pregnant women (7-41 gestational weeks) including normal pregnant women (60 cases) and pre-eclamptic pregnant women (20 cases) were selected as study groups and 20 normal non-pregnant women were selected as control group. Free DNA of plasma samples was extracted, and RASSF1A levels before and after double-methylation-sensitive restriction enzyme digestion of HinP1I and HhaI were determined to measure total and fetal cell-free DNA, respectively. beta-Actin gene was detected as a control to confirm complete enzyme digestion. RESULTS: The median concentrations of hypermethylated RASSF1A gene were 46 copies/mL in first trimester, 96 copies/mL in second trimester, 527 copies/mL in third trimester and 1947 copies/mL in pre-eclampsia. There was positive correlation between fetal-derived hypermethylated RASSF1A levels and the severity of pre-eclampsia. CONCLUSION: Hypermethylated RASSF1A gene may be considered as an epigenetic marker to detect the fetal DNA in maternal plasma and expands the clinical application of non-invasive prenatal diagnosis. (c) 2010 John Wiley & Sons, Ltd.
Authors: Robert M Silver; Leslie Myatt; John C Hauth; Kenneth J Leveno; Alan M Peaceman; Susan M Ramin; Philip Samuels; George Saade; Yoram Sorokin; Rebecca G Clifton; Uma M Reddy Journal: Am J Perinatol Date: 2016-07-11 Impact factor: 1.862
Authors: Stacy Beck; Irina A Buhimschi; Taryn L Summerfield; William E Ackerman; Ozlem Guzeloglu-Kayisli; Umit A Kayisli; Guomao Zhao; Frederick Schatz; Charles J Lockwood; Catalin S Buhimschi Journal: Am J Reprod Immunol Date: 2019-03-04 Impact factor: 3.886
Authors: Jessica M E van den Oever; Sahila Balkassmi; Tim Segboer; E Joanne Verweij; Pieter A van der Velden; Dick Oepkes; Egbert Bakker; Elles M J Boon Journal: PLoS One Date: 2013-12-31 Impact factor: 3.240
Authors: Hyun Jin Kim; Shin Young Kim; Ji Hyae Lim; Dong Wook Kwak; So Yeon Park; Hyun Mee Ryu Journal: Int J Mol Sci Date: 2015-12-15 Impact factor: 5.923